-
1
-
-
11144354339
-
Prevalence of age-related macular degeneration in the United States
-
Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-572.
-
(2004)
Arch Ophthalmol
, vol.122
, pp. 564-572
-
-
Friedman, D.S.1
O'Colmain, B.J.2
Munoz, B.3
-
2
-
-
0021752680
-
Age-related macular degeneration and blindness due to neovascular maculopathy
-
Ferris FL, Fine SL, Hyman L: Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-1642.
-
(1984)
Arch Ophthalmol
, vol.102
, pp. 1640-1642
-
-
Ferris, F.L.1
Fine, S.L.2
Hyman, L.3
-
3
-
-
0026681119
-
Prevalence of age-related maculopathy the Beaver Dam Eye Study
-
Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99:933-943.
-
(1992)
Ophthalmology
, vol.99
, pp. 933-943
-
-
Klein, R.1
Klein, B.E.2
Linton, K.L.3
-
4
-
-
0034102998
-
Hypertension, cardiovascular disease, and age-related macular degeneration Age-Related Macular Degeneration Risk Factors Study Group
-
Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118:351-358.
-
(2000)
Arch Ophthalmol
, vol.118
, pp. 351-358
-
-
Hyman, L.1
Schachat, A.P.2
He, Q.3
-
5
-
-
34249680358
-
Cardiovascular risk factors and the long-Derm incidence of age-related macular degeneration: The Blue Mountains Eye Study
-
Tan JS, Mitchell P, Smith W, et al. Cardiovascular risk factors and the long-Derm incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007; 114:1143-1150.
-
(2007)
Ophthalmology
, vol.114
, pp. 1143-1150
-
-
Tan, J.S.1
Mitchell, P.2
Smith, W.3
-
6
-
-
16244368037
-
Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report No 19
-
Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report No. 19. Ophthalmology 2005; 112:533-539.
-
(2005)
Ophthalmology
, vol.112
, pp. 533-539
-
-
Clemons, T.E.1
Milton, R.C.2
Klein, R.3
-
7
-
-
20244380171
-
Complement factor H polymorphism in age-related macular degeneration
-
Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-389.
-
(2005)
Science
, vol.308
, pp. 385-389
-
-
Klein, R.J.1
Zeiss, C.2
Chew, E.Y.3
-
8
-
-
84887210076
-
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration
-
Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013; 120:2317-2323.
-
(2013)
Ophthalmology
, vol.120
, pp. 2317-2323
-
-
Awh, C.C.1
Lane, A.M.2
Hawken, S.3
-
9
-
-
0031873513
-
Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye
-
Pieramici DJ, Bressler SB: Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye. Curr Opin Ophthalmol 1998; 9:38-46.
-
(1998)
Curr Opin Ophthalmol
, vol.9
, pp. 38-46
-
-
Pieramici, D.J.1
Bressler, S.B.2
-
10
-
-
8544234955
-
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Macular Photocoagulation Study Group
-
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Macular Photocoagulation Study Group. Arch Ophthalmol 1997 115 741-747.
-
(1997)
Arch Ophthalmol
, vol.115
, pp. 741-747
-
-
-
11
-
-
33746373850
-
Age-related macular degeneration (AMD): Pathogenesis and therapy
-
Nowak JZ: Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58:353-363.
-
(2006)
Pharmacol Rep
, vol.58
, pp. 353-363
-
-
Nowak, J.Z.1
-
12
-
-
0142122287
-
Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition
-
Das A, McGuire PG: Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22:721-748.
-
(2003)
Prog Retin Eye Res
, vol.22
, pp. 721-748
-
-
Das, A.1
McGuire, P.G.2
-
13
-
-
84861722422
-
What are the half-lives of ranibizumab and aflibercept (VEGF Trap-Eye) in human eyes? Calculations with a mathematical model
-
Stewart MW: What are the half-lives of ranibizumab and aflibercept (VEGF Trap-Eye) in human eyes? Calculations with a mathematical model. Eye Reports 2011; 1:e5.
-
(2011)
Eye Reports
, vol.1
, pp. e5
-
-
Stewart, M.W.1
-
14
-
-
0029831672
-
Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
-
Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-1934.
-
(1996)
Invest Ophthalmol Vis Sci
, vol.37
, pp. 1929-1934
-
-
Kvanta, A.1
Algvere, P.V.2
Berglin, L.3
-
15
-
-
0029935043
-
Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation
-
Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80:363-366.
-
(1996)
Br J Ophthalmol
, vol.80
, pp. 363-366
-
-
Wells, J.A.1
Murthy, R.2
Chibber, R.3
-
16
-
-
0030952289
-
Mechanisms of angiogenesis
-
Risau W: Mechanisms of angiogenesis. Nature 1997; 386:671-674.
-
(1997)
Nature
, vol.386
, pp. 671-674
-
-
Risau, W.1
-
17
-
-
0344541763
-
Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes
-
Grossniklaus HE, Gass JD: Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126:59-69.
-
(1998)
Am J Ophthalmol
, vol.126
, pp. 59-69
-
-
Grossniklaus, H.E.1
Gass, J.D.2
-
18
-
-
33644873981
-
Neovascular age-related macular degeneration: Natural history and treatment outcomes
-
Pauleikhoff D: Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005; 25:1065-1084.
-
(2005)
Retina
, vol.25
, pp. 1065-1084
-
-
Pauleikhoff, D.1
-
19
-
-
0035009086
-
Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration.
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131:541-560.
-
(2001)
Am J Ophthalmol
, vol.131
, pp. 541-560
-
-
-
20
-
-
0035124965
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-DAP report 2
-
Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-DAP report 2. Arch Ophthalmol 2001; 119:198-207.
-
(2001)
Arch Ophthalmol
, vol.119
, pp. 198-207
-
-
Bressler, N.M.1
-
21
-
-
37449010146
-
The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-Analysis
-
Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-Analysis. Ophthalmology 2008; 115:116-126.
-
(2008)
Ophthalmology
, vol.115
, pp. 116-126
-
-
Wong, T.1
Chakravarthy, U.2
Klein, R.3
-
22
-
-
0026409933
-
Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group
-
Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991 109 1109-1114.
-
(1991)
Arch Ophthalmol
, vol.109
, pp. 1109-1114
-
-
-
23
-
-
0028349664
-
Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration Macular Photocoagulation Study Group
-
Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration Macular Photocoagulation Study Group. Arch Ophthalmol 1994 112 489-499.
-
(1994)
Arch Ophthalmol
, vol.112
, pp. 489-499
-
-
-
24
-
-
7444227954
-
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SST report No 11
-
Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report No. 11. Ophthalmology 2004; 111:1967-1980.
-
(2004)
Ophthalmology
, vol.111
, pp. 1967-1980
-
-
Hawkins, B.S.1
Bressler, N.M.2
Miskala, P.H.3
-
25
-
-
33747891752
-
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
-
Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508.e1-1508.e25.
-
(2006)
Ophthalmology
, vol.113
, pp. 1508e1-1508e25
-
-
Chakravarthy, U.1
Adamis, A.P.2
Cunningham, E.T.3
-
26
-
-
11144239923
-
Pegaptanib for neovascular age-related macular degeneration
-
Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816.
-
(2004)
N Engl J Med
, vol.351
, pp. 2805-2816
-
-
Gragoudas, E.S.1
Adamis, A.P.2
Cunningham, E.T.3
-
27
-
-
33749445317
-
Ranibizumab for neovascular age-related macular degeneration
-
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431.
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
-
28
-
-
33749451356
-
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
-
Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
-
29
-
-
57949094834
-
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
-
ANCHOR Study Group.
-
Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116:57-65.
-
(2009)
Ophthalmology
, vol.116
, pp. 57-65
-
-
Brown, D.M.1
Michels, M.2
Kaiser, P.K.3
-
30
-
-
43049176776
-
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results
-
Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862-874.
-
(2008)
Am J Ophthalmol
, vol.145
, pp. 862-874
-
-
Antoszyk, A.N.1
Tuomi, L.2
Chung, C.Y.3
-
31
-
-
34548721616
-
Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
-
Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627-637.
-
(2007)
Am J Ophthalmol
, vol.144
, pp. 627-637
-
-
Brown, D.M.1
Regillo, C.D.2
-
32
-
-
33947403618
-
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
-
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583.
-
(2007)
Am J Ophthalmol
, vol.143
, pp. 566-583
-
-
Fung, A.E.1
Lalwani, G.A.2
Rosenfeld, P.J.3
-
33
-
-
84877759606
-
Twelve-month efficacy and safety of 0.5 or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
-
HARBOR Study Group.
-
Busbee BG, Ho AC, Brown DM, et al. HARBOR Study Group: Twelve-month efficacy and safety of 0.5 or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120:1046-1056.
-
(2013)
Ophthalmology
, vol.120
, pp. 1046-1056
-
-
Busbee, B.G.1
Ho, A.C.2
Brown, D.M.3
-
34
-
-
84908469619
-
Systemic vascular safety of ranibizumab for age-related macular degeneration
-
Ueta T, Noda Y, Toyama T, et al Systemic vascular safety of ranibizumab for age-related macular degeneration. Ophthalmology 2014 121 2193-2203.
-
(2014)
Ophthalmology
, vol.121
, pp. 2193-2203
-
-
Ueta, T.1
Noda, Y.2
Toyama, T.3
-
35
-
-
20144372969
-
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
-
Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-1047.
-
(2005)
Ophthalmology
, vol.112
, pp. 1035-1047
-
-
Michels, S.1
Rosenfeld, P.J.2
Puliafito, C.A.3
-
36
-
-
33745091547
-
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
-
Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-390.
-
(2006)
Retina
, vol.26
, pp. 383-390
-
-
Spaide, R.F.1
Laud, K.2
Fine, H.F.3
-
37
-
-
36549039554
-
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
-
Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
-
(2007)
Ophthalmology
, vol.114
, pp. 2179-2182
-
-
Bakri, S.J.1
Snyder, M.R.2
Reid, J.M.3
-
39
-
-
79956218863
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
-
CATT Research Group.
-
Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-908.
-
(2011)
N Engl J Med
, vol.364
, pp. 1897-1908
-
-
Martin, D.F.1
Maguire, M.G.2
Ying, G.S.3
-
40
-
-
84863320414
-
Ranibizumab and bevacizumab for neovascular age-related macular degeneration: Two-year results
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group
-
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398.
-
(2012)
Ophthalmology
, vol.119
, pp. 1388-1398
-
-
Martin, D.F.1
Maguire, M.G.2
Fine, S.L.3
-
41
-
-
84863327423
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
-
IVAN Study Investigators
-
IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399-1411.
-
(2012)
Ophthalmology
, vol.119
, pp. 1399-1411
-
-
Chakravarthy, U.1
Harding, S.P.2
Rogers, C.A.3
-
42
-
-
84886430519
-
Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 year findings of the IVAN randomized controlled trial
-
IVAN Study Investigators.
-
Chakravarthy U, Harding SP, Rogers CA, et al. IVAN Study Investigators: Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 year findings of the IVAN randomized controlled trial. Lancet 2013; 382:1258-1267.
-
(2013)
Lancet
, vol.382
, pp. 1258-1267
-
-
Chakravarthy, U.1
Harding, S.P.2
Rogers, C.A.3
-
43
-
-
84887176870
-
Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL Noninferiority Randomized Trial
-
GEFAL Study Group.
-
Kodjikian L, Souied EH, Minoun G, et al. GEFAL Study Group: Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013; 120:2300-2309.
-
(2013)
Ophthalmology
, vol.120
, pp. 2300-2309
-
-
Kodjikian, L.1
Souied, E.H.2
Minoun, G.3
-
44
-
-
84874654113
-
A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
-
MANTA Research Group.
-
Krebs I, Schmetterer L, Boltz A, et al. MANTA Research Group: A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013; 97:266-271.
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 266-271
-
-
Krebs, I.1
Schmetterer, L.2
Boltz, A.3
-
45
-
-
84920748073
-
Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-And-extend protocol
-
Berg K, Pederson TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-And-extend protocol. Ophthalmology 2015; 122:146-152.
-
(2015)
Ophthalmology
, vol.122
, pp. 146-152
-
-
Berg, K.1
Pederson, T.R.2
Sandvik, L.3
-
46
-
-
0037143764
-
VEGF-Drap: A VEGF blocker with potent antitumor effects
-
Holash J, Davis S, Papadopoulos N, et al. VEGF-Drap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 11393-11398
-
-
Holash, J.1
Davis, S.2
Papadopoulos, N.3
-
47
-
-
84865129521
-
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
-
Papadopoulos N, Martin J, Run Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15:171-185.
-
(2012)
Angiogenesis
, vol.15
, pp. 171-185
-
-
Papadopoulos, N.1
Martin, J.2
Run, Q.3
-
50
-
-
84891631034
-
Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of VIEW studies
-
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of VIEW studies. Ophthalmology 2014; 121:193-201.
-
(2014)
Ophthalmology
, vol.121
, pp. 193-201
-
-
Schmidt-Erfurth, U.1
Kaiser, P.K.2
Korobelnik, J.F.3
-
52
-
-
79955085045
-
Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% of 2008 Medicare fee-for-service part B claims file
-
Brechner, RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% of 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol 2011; 151:887-895.
-
(2011)
Am J Ophthalmol
, vol.151
, pp. 887-895
-
-
Brechner, R.J.1
Rosenfeld, P.J.2
Babish, J.D.3
-
54
-
-
84860450956
-
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of DENALI study
-
Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of DENALI study. Ophthalmology 2012; 119:1001-1010.
-
(2012)
Ophthalmology
, vol.119
, pp. 1001-1010
-
-
Kaiser, P.K.1
Boyer, D.S.2
Cruess, A.F.3
-
55
-
-
84860452217
-
Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of MONT BLANC study
-
Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of MONT BLANC study. Ophthalmology 2012; 119:992-1000.
-
(2012)
Ophthalmology
, vol.119
, pp. 992-1000
-
-
Larsen, M.1
Schmidt-Erfurth, U.2
Lanzetta, P.3
-
57
-
-
0024566535
-
A light microscopic and autoradiographic study of non-irridiated and irradiated ocular wounds
-
Chakravarthy U, Gardinder TA, Archer DB, et al. A light microscopic and autoradiographic study of non-irridiated and irradiated ocular wounds. Curr Eye Res 1989; 8:337-348.
-
(1989)
Curr Eye Res
, vol.8
, pp. 337-348
-
-
Chakravarthy, U.1
Gardinder, T.A.2
Archer, D.B.3
-
58
-
-
61749100479
-
Twelve-month short-Derm safety and visual-Acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
-
Avila MP, Farah ME, Santos A, Duprat JP, et al. Twelve-month short-Derm safety and visual-Acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009; 93:305-309.
-
(2009)
Br J Ophthalmol
, vol.93
, pp. 305-309
-
-
Avila, M.P.1
Farah, M.E.2
Santos, A.3
Duprat, J.P.4
-
59
-
-
84873316131
-
Epimacular brachytherapy for neovascular age-related macular degeneration: A randomized, controlled trial (CABERNET)
-
Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013; 120:317-327.
-
(2013)
Ophthalmology
, vol.120
, pp. 317-327
-
-
Dugel, P.U.1
Bebchuk, J.D.2
Nau, J.3
-
62
-
-
84947293579
-
-
Dugel PU. American Academy of Ophthalmology Annual Meeting, Chicago, November 10
-
Dugel PU: Anti-platelet-derived growth factor: where do we stand? American Academy of Ophthalmology Annual Meeting, Chicago, November 10, 2012.
-
(2012)
Anti-platelet-derived Growth Factor: Where Do We Stand?
-
-
-
63
-
-
77953530014
-
Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a phase 1 study
-
Ophthotech Anti-PDGF in AMD Study Group E-Abstract 1260
-
Boyer DS; Ophthotech Anti-PDGF in AMD Study Group: Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a phase 1 study. Invest Ophthalmol Vis Sci 2009; 50:E-Abstract 1260.
-
(2009)
Invest Ophthalmol Vis Sci
, vol.50
-
-
Boyer, D.S.1
-
64
-
-
0025837828
-
Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: Results of a randomized clinical trial
-
Macular Photocoagulation Study Group.
-
Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-1231.
-
(1991)
Arch Ophthalmol
, vol.109
, pp. 1220-1231
-
-
-
65
-
-
1942525885
-
Occult choroidal neovascularization Influence on visual outcome in patients with age-related macular degeneration
-
Macular Photocoagulation Study Group.
-
Macular Photocoagulation Study Group: Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996; 114:400-412.
-
(1996)
Arch Ophthalmol
, vol.114
, pp. 400-412
-
-
|